Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT03555201 Completed - Clinical trials for Temporomandibular Dysfunction (TMD)

Efficacy of Physiotherapy in Patients With Temporomandibular Disorders.

MT-ATM
Start date: May 31, 2018
Phase: N/A
Study type: Interventional

Objective: To evaluate the efficacy of a manual therapy protocol composed of articulatory and myofascial techniques in patients with temporomandibular dysfunction (TMD). Methods: Randomized and controlled clinical study of patients presenting TMD. The subjects will be divided into 2 groups: 1) manual therapy group; 2) control group. There will be 4 treatment sessions during 4 weeks, with evaluations before and after the study, which include: severity of dysfunction (Helkimo Index), quality of life (Short Form 36 Health Survey), pressure pain threshold (algometer) ), cervical mobility (goniometer), mouth opening (caliper), pain intensity (Visual Analogue Scale) and cervical disability (Neck Disability Index).

NCT ID: NCT03554655 Completed - Clinical trials for Schizophrenia, Schizotypal and Delusional Disorders

The Efficacy of Using a Smartphone App to Support Shared Decision Making in People With a Diagnosis of Schizophrenia

Start date: January 7, 2019
Phase: N/A
Study type: Interventional

This study investigates the effects of using a smartphone app to support shared decision making (SDM) for people with schizophrenia-spectrum disorders in an outpatient treatment setting. Patients are randomized to specialized early intervention treatment with the Momentum app or without the app. The primary objective is to investigate the effect of the app on patient activation 6 months after baseline. Secondary outcomes are positive and negative symptoms, level of functioning; working alliance; self-efficacy; treatment satisfaction; hope; level of SDM; and perceived efficacy in patient-provider interaction. Explorative outcomes are self-perceived usefulness of the Momentum app.

NCT ID: NCT03554304 Completed - Clinical trials for QT/QTc Interval in Healthy Volunteers

Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers

Start date: February 9, 2017
Phase: Phase 1
Study type: Interventional

A Randomized, Double-Blind, Double-Dummy, Placebo- and Positive-Controlled, Crossover Study to Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers

NCT ID: NCT03554252 Completed - Clinical trials for Health Knowledge, Attitudes, Practice

Comparison of Different Frames of Numerical Information in Cochrane Plain Language Summaries

Start date: April 1, 2018
Phase: N/A
Study type: Interventional

Participants will be randomly given one of two formats containing descriptions of health interventions. In one format, participants will have to read short summaries where results of the intervention are presented as frequencies and the side effects of health intervention are presented as percentages, while in another format the frames will be reversed (results will be presented as percentages and side effects as frequencies). After reading, participants will be asked several questions about the content of the summary and its conclusions.

NCT ID: NCT03553706 Completed - Clinical trials for Down Syndrome,Auxological Indexes, Auxological Parametars, Intrauterine Growth Restriction

Indicators of Growth, Nutritional Status and Comorbide Disorders of Newborns With Down Syndrome

DownSy
Start date: May 20, 2018
Phase:
Study type: Observational

Objective To access predictive values of the auxological parameters and indexes for risk of comorbid malformations in newborns with Down syndrome (DS) Study design In this cohort retrospective study, 141 newborns with proven trisomy 21 born at the Department of Gynecology and Obstetrics of the University of Split Hospital (1990 to 2015) were included. The data were obtained from the medical histories of mothers, infants and the delivery protocol. The objective was to access predictive values of the auxological parameters and indexes for risk of comorbid malformations in newborns with Down syndrome (DS) Conclusion Higher CI were found in hyportrophic (SGA) newborns with DS and indicated their intrauterine growth restriction with brain sparing and increased further risk of severe psychomotor retardation. The SGA newborns have lower parameters and indexes of nutritive status and significantly differed from eutrophic and hypertrophic newborns. These SGA newborns with DS have increased developmental risks and that requires further diagnostic attention.

NCT ID: NCT03553641 Completed - Clinical trials for Symptomatic Irreversible Pulpitis

The Effect of Central Sensitization on Assessment Capacity of Patients

Start date: November 1, 2017
Phase:
Study type: Observational [Patient Registry]

the aim of this study is to evaluate the effect of dental hyperalgesia and mechanical allodynia on the assessment capacity of individuals in a local Turkish population. The hypothesis of this study is that excessive amounts of pain and a major functional shift in the somatosensory system due to central sensitization might cause unwitting intent.

NCT ID: NCT03553329 Completed - Clinical trials for Unresecable Stage IIIc or IV Melanoma

Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti BRAF and Anti MEK

SVALMEL
Start date: June 2, 2018
Phase:
Study type: Observational

The therapeutic arsenal of metastatic melanoma has changed considerably over the past 10 years. The treatment of metastatic melanoma is now based on immunotherapy and targeted therapies, while the place of conventional chemotherapy becomes more restricted. Targeted therapies are indicated for BRAF mutated melanomas. The mutation BRAF leads activation of MAP Kinases pathway and the proliferation of melanoma cell in the body . About 50% of metastatic melanoma is BRAF mutated. The most frequent mutation is the V600E. The targeted therapy by anti BRAF and anti MEK allows the double bloking of the MAP Kinases pathway. This treatment is more efficient than that of the anti BRAF alone. The association of anti BRAF and anti MEK have a global survival global rate of 41% at the 1 year, against 9% for the anti BRAF . In 2014, a program of extended access to the association of anti BRAF and anti MEK (dabrafenib and trametinib) started in many french hospitals (Protocol Mekinist, Novartis laboratory). Patients who were included in this program and followed in Poitiers Hospital, had frequent abnormalities of albumin level without any sign of undernutrition. Hypoabuminemia is a poor prognosis factor described in many cancers, including metastatic melanoma. The only prognostic factor in metastatic melanoma is the rate of LDH . The level of albumin and its prognostic impact have not been studied for patients with a metastatic melanoma and treated by anti BRAF and anti MEK. The objective of this studie was to analyze the variations of albumin level in patients with unresecable stage IIIc or stage IV melanoma treated in our Center by dabrafenib and trametinib

NCT ID: NCT03552666 Completed - Clinical trials for Bioequivalence of Vitamin D in Healthy Adults

Clinical Study on the Bioequivalence of Vitamin D in Healthy Adults

Start date: December 26, 2016
Phase: N/A
Study type: Interventional

The objective of this clinical study is to evaluate and compare the bioequivalence between a single oral dose of vitamin D3 gummy vitamin versus vitamin D3 tablet in healthy adults.

NCT ID: NCT03552653 Completed - Clinical trials for Measure Absorption of Vitamin D in Blood

Bioequivalence Study on Vitamin D in Healthy Adults

Start date: August 26, 2017
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate and compare the bioequivalence between a single oral dose of vitamin D3 gummy vitamin versus vitamin D3 tablet in healthy adults.

NCT ID: NCT03552510 Completed - Preterm Infant Clinical Trials

Oropharyngeal Administration of Mother's Milk in Preterm Infants and Gastrointestinal Motility

OPAMM
Start date: June 1, 2016
Phase: N/A
Study type: Interventional

Mother's milk does not come in contact with the oropharyngeal pouch of preterm infants during gavage feeding. We hypothesized that stimulation of the oropharyngeal pouch using small amount of the mother's milk 5 minutes before initiation of regular gavage feeding will increase the level of GIT hormones.